ArticleTargeted oncology2016

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.

Maria Pinkerneil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.